Imagin Medical Inc. (C:IME)
Business Focus: Bio Medical Devices
You may also be interested in
Insider Filings
Latest 10 SEDI filings for IME within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
See Short Report
Loading...
Company News
Feb 05, 2024 07:13 ET
Canadian Investment Regulatory Organization Trading Halt - IME
VANCOUVER, BC, Feb. 5, 2024 /CNW/ - The following issues have been halted by CIRO:
Apr 22, 2022 16:15 ET
Imagin Medical Announces Stock Option Grants
VANCOUVER, BC and BOSTON, April 22, 2022 /PRNewswire/ -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company") today announced today that, pursuant to the Company's Stock Option Plan, an aggregate of 472,187 shares have been granted to certain employees, board members and consultants as incentive stock options at an exercise price of $0.28 USD per share. The options are exercisable for a period of five years, ending on April 22, 2027.
Valuation Ratios
Industry
Sector
Beta
1.14
--
--
Price to Sales - TTM
--
22.54
3.83
Price to Book - most recent quarter
--
--
2.08
Price to Cash Flow per share - TTM
--
--
9.68
Price to Free Cash Flow per share - TTM
--
--
14.80
Short Report
| Date | Number of Shares Shorted | Net Change |
|---|---|---|
| Jan 31, 2024 | 60,200 | 0 |
| Dec 15, 2023 | 92 | 0 |
| Nov 30, 2023 | 92 | -91 |
Business Summary
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
